Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy
about
Distribution of CYP2D6 alleles and phenotypes in the Brazilian populationAnalytical validation of genotyping assays in the biomarker laboratory.A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genesIntroduction: genetic variation and human healthMicroRNA-mediated drug resistance in breast cancer.Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patientsBiomarkers: symptoms, survivorship, and quality of lifeEffect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models.Genelex Corporation.PhRMA white paper on ADME pharmacogenomics.Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein.Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.Metabolism of ophthalmic timolol: new aspects of an old drug.Complexities of CYP2D6 gene analysis and interpretation.Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.Patient preferences for pharmacogenetic screening in depression.Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians.Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants.Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.DrugBank and its relevance to pharmacogenomics.Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico.Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients.Pregnancy and pharmacogenomics in the context of drug metabolism and response.
P2860
Q28543940-12F64590-0309-4230-A6C7-315FA212FC71Q33280254-9AE56AB3-182B-41E9-B092-E3428B811CA5Q33552774-93C02F4E-44FD-44BA-A07E-9F88C02B950FQ34789161-18DC9EB0-B8FF-420E-A13F-B5E1BBA69F8FQ35020657-527A7949-2438-4635-A02D-B097886D7DB6Q35038060-104F5AC6-7520-49ED-B96D-9F40F650D051Q35165126-C616C310-A6A8-43B1-9A60-461CEA833A4FQ35575577-784A3B8E-F4CE-4671-832C-3417942E760DQ35923511-0CF77074-6FE3-4CAC-BDBC-857EF6368ED7Q36558437-0A0F3FDF-E27B-4317-8CFD-6C4054A2229EQ36596713-F1E5F6E5-9200-4860-99A7-B7BBB54B3773Q36761673-BC9906AE-EB7C-470C-997A-B82B476BB2B7Q36812371-8436ADF9-0A6B-4468-814A-7A4D3ED535DBQ37126673-1C9A2B6A-1EBF-4DA9-853A-CA56F6C9EB8DQ37182212-134F2FD8-A451-4AC7-8A6D-C22A9F944C9DQ37298808-3C68963C-49E6-4E41-A6C7-FDB5A33DDBA4Q37337092-E6CF26F2-05CE-4B0F-B26F-73203D3D3B36Q37551896-37A9E92B-49A5-4D86-80D7-BBE61E9C4EAFQ37663390-38011128-F1F6-474E-94F9-FFA61F0B4A14Q37850837-11889038-6448-4E82-B038-14EE7EF6D5DBQ38154914-A05D6976-A8B5-4B06-B40E-5F9F8ADDE456Q38240768-F0B9E59E-A214-49C7-9D88-DA1F4A48A6D8Q38553911-33B88601-F7A7-4244-A195-9F5AF646FFC5Q39324637-D6267F54-2576-4F95-B878-8B6E3418DA0FQ39946483-3F74989D-8BD5-4C82-9518-259CEE856356Q41959654-C97C6114-293B-453A-9D44-7A862161BB49Q44502093-2CDC1938-8EAA-48C8-AACF-07F70298F4A3Q44950782-5B6EE309-A2BF-4988-9050-3F8B0A6700AAQ46298744-72374287-2DF4-4755-B584-242A9B316C8CQ47772546-22775B72-D8CE-4DA1-B8BC-89DF02670B80Q53621350-2B24DEC1-72DA-4B07-9B87-8FE167003DB4Q54659609-1F52F271-A9A2-4BC7-AC4B-A5C306CCA11B
P2860
Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@ast
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@en
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@nl
type
label
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@ast
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@en
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@nl
prefLabel
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@ast
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@en
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@nl
P2860
P356
P1476
Pharmacogenetics of drug-metab ...... nd more effective drug therapy
@en
P2093
Cristina Rodriguez-Antona
P2860
P304
P356
10.1098/RSTB.2005.1685
P407
P577
2005-08-29T00:00:00Z